SH2-containing inositol 5ʹ-phosphatase-1 (SHIP1) deficiency in mice results in abnormal myeloid expansion, and proinflammatory conditions in the lung. However, the mechanisms involved in SHIP1mediated regulation of myeloid differentiation remain unclear. Here we show that SHIP1 is a key regulator of early differentiation for dendritic cells (DCs). We also provide critical evidence to modify the function of SHIP1 in in vitro development of BMDCs using the recent framework of defining DCs. We found that loss of SHIP1 suppresses GM-CSF-induced formation of bone marrow-derived DC (BMDC) colonies, leading to reduced BMDC number in BM cell culture. The number of maturated BMDCs decreased in SHIP1-KO culture, due to reduction of immature BMDCs, suggesting SHIP1 is critical for lineage commitment rather than for maturation from myeloid precursors to DCs. We further showed that F4/80 + /MHCII low BM macrophage-like cells (BMMs) were the main population of SHIP1-KO BM culture. Treatment of wild-type BM culture with 3 α-aminocholestane (3AC), a specific inhibitor for functional activity of SHIP1, caused a similar developmental defect in BMDCs as seen in SHIP1-KO cells, resulting in the absence of BMDC colony, and increased number of BMMs in BM culture. In conclusion, our results suggest that differentiation of BMDCs are markedly impaired under SHIP1 deficient condition, which causes skewed development of myeloid lineage cells manifested as pathological conditions associated with an excess of macrophage population.
Introduction
Dendritic cells (DCs) and macrophages play a critical role in the regulation of the immune response, mainly through antigen presentation and cytokine/chemokine production. 1 A common precursor develops into a myeloid lineage cells in the bone marrow (BM), and these cells are matured in peripheral tissues through interaction with antigens and cytokines in their microenvironment. In vitro treatment of whole BM cells with granulocyte macrophage colony-stimulating factor (GM-CSF) induces these cells to differentiate into macrophages-like cells (BMMs) and dendritic cells (BMDCs). 2 In addition, stimulation of BM cells with Flt3ligand (Flt3-L) induces their differentiation into plasmacytoid DCs (pDCs), which are powerful cytokine producing cells. 3 SH2-containing inositol 5ʹ-phosphatase-1 (SHIP1) hydrolyzes phosphatidylinositol (3, 4, 5) -trisphosphate [PtdIns (3, 4, 5) P 3 ] into phosphatidylinositol (3, 4) -bisphosphate [PtdIns (3, 4) P 2 ] and thus down-regulates the action of phosphatidylinositol 3-kinase (PI3K), which catalyzes the production of PtdIns (3,4,5)P 3 . PTEN also displays inhibitory activity of the PI3K signaling, but its enzymatic activation of the inositol phosphatases is distinct in that PTEN generates PtdIns(4,5)P 2 from PtdIns(3,4,5)P 3 . 4 Unlike PTEN product PtdIns(4,5)P 2 , SHIP1 product PtdIns(3,4)P 2 have great affinity to pleckstrin homology(PH) domain of Akt and thus contributes to the activation of PI3K/Akt axis, 5 leading to growth and survival of tumor cells. 6 Although treatment with 3 a-aminocholestane (3AC), specific SHIP1 inhibitor, increases the phosphorylation of Akt, and at the same time has been reported to suppresses the proliferation and triggers apoptosis of hematopoietic cancer cells. 7, 8 Therefore, targeting SHIP1 has been suggested as a potential therapeutic application in the treatment of certain cancers. 9 SHIP1-KO mice have increased numbers of granulocytes, macrophages, and myeloid-derived suppressor cells, leading to multiple immunological abnormalities. 10, 11 Furthermore, recent studies have shown that either loss of SHIP1 gene or functional inactivation by 3AC in mice can enhance immunoregulatory potential of the host immunity by increasing the numbers of both myeloid-derived suppressor cells and regulatory T cells. 7, 12 Using BMDCs and spleen DCs from SHIP1-KO mice, two independent groups previously showed that SHIP1 is required for dendritic cell maturation. These studies propelled others to evaluate the role of SHIP1 in cellular function of DCs related to helminth infection and graft versus host disease (GvHD). [13] [14] [15] However, it remains unclear as how SHIP1 affects the differentiation and maturation of myeloid cells, such as DCs and macrophages.
It is noteworthy that in previous studies the separation of BMDCs from BM culture was based on the expression of a single phenotypic marker, 16, 17 CD11c, which is inadequate to distinguish BMDCs and BMMs. In GM-CSF-induced BM cultures, CD11c + cells were mainly composed of two populations based on the MHCII and F4/80 expressions. 18 BMDCs have MHCII med-high CD11c + F4/80 low phenotype, while BMMs are MHCII low CD11c + F4/80 high . 19 Furthermore, BMDCs can be divided into two populations, immature and mature cells depending on the level of MHCII (moderate versus high expression, respectively). 20 Examining the expression of costimulation molecules, such as CD86, can provide additional confirmation of the maturation of BMDCs. Therefore, a clear characterization of BMDCs and BMMs in GM-CSF-induced BM culture will facilitate our understanding of the role of SHIP1 has in myeloid development.
In this study, we found that GM-CSF-induced colonization, a critical first step in CSF-induced myeloid development, was suppressed in SHIP1-KO BM cultures. Further, through flow cytometry cell analysis, we showed that SHIP1-KO precursors rarely developed into immature BMDCs until day 6 in BM cell cultures. In contrast, wild-type precursors gradually differentiated into CD11c + /MHCII med (immature) DCs as early as day 3 in BM cell cultures. These results suggest that SHIP1 is required for the early differentiation of DCs from myeloid precursor cells (MPs), rather than for antigen-induced maturation as seen at the later stages as described by several reports. 16, 17 Therefore, loss of SHIP1 causes abnormal development of myeloid lineages, leading to increased number of macrophage-like cells in the BM at the expense of DC differentiation.
Results

SHIP1 is required for GM-CSF-induced differentiation of myeloid precursors
To assess the impact of SHIP1 deficiency on differentiation of myeloid precursors into DCs, mouse BM cells were isolated from wild-type and SHIP1-KO mice, and cultured with GM-CSF for 8 days. LPS were added into BM cultures at day 8 to examine the final maturation of BMDCs ( Figure 1A ). As described previously, 2 BMDCs are commonly recognized in cell culture by day 3~4 as cellular aggregates attached to a layer of adherent cells in GM-CSF containing media. The adherent cells have the morphological features of macrophages. Through microscopic observation, we found that in the SHIP1-KO BM cell culture fewer cellular aggregates were seen at day 3 and day 5, whereas these cellular aggregates were commonly found in wild-type BM cell culture at this developmental stage ( Figure 1B ). These data indicated that GM-CSF-induced colonization is suppressed in SHIP1-deficient Figure 1 . GM-CSF-induced colonization of BMDCs. (A) Experimental scheme for in vitro culture for BMDCs. BM cells were isolated from femur and tibia of wild-type (WT) and SHIP-KO (KO) mice. Suspension cells were removed from total BM cells culture (Total), total cells were observed prior to harvesting suspension cells. Cell morphologies of total cells and adherent cell cultures were photographed on day 3 (B) and day 5 (C). Pictures were representative images of three independent observations. Scale bar = 100 μm. myeloid precursors, suggesting that SHIP1 deficiency inhibits growth factor-induced colonization for DC development. Also, these colonies were still detected in adherent population (Adh, of wild-type) after harvesting suspension/low-adherent cells, suggesting that adherent populations still contain differentiating DCs, and a suspension protocol is not enough to isolate BMDCs completely from BM culture. Therefore, in order to examine the differentiation of BMDC in BM culture, we must analyze both suspension and adherent cell populations.
SHIP1 is required for optimal BMDCs differentiation from precursors
It is possible that GM-CSF-induced DC differentiation is impaired and skewing to other cells in SHIP1-KO BM culture due to the failure of colonization. To examine this hypothesis, a dual staining method with antibodies against mouse CD11c and against mouse MHCII was carried out. Triple staining of CD11c, MHCII and CD86 was also performed to examine the ratio of maturation of BMDCs (Figure 2A ). 20 First, we observed increased number of total cells in SHIP1-KO BM culture compared to wild-type BM culture ( Figure 2B ) as previously described. 17 However, the effect on proliferation was not significant at the later time points (day 6 and 8). To determine the role of SHIP1 in differentiation and maturation of BMDCs, we examined various cell populations in BM culture. We cultured BM cells from wild-type or SHIP1-KO mice, and the cells were separately harvested into suspension cells and adherent cells, respectively. Suspension cells were collected from the media by pipetting, and then adherent cells were completely harvested by scraping. Both suspension and adherent cell populations were analyzed by flow-cytometry using antibodies against CD11c/MHCII ( Figure 2C ), or CD11c/CD86 ( Figure 2D ). Immature DCs and mature DCs are distinguished by the expression pattern of MHCII and CD86 in CD11c positive BM cells. 20 In SHIP1-KO BM cultures, the number of CD11c + /MHCII med immature DCs significantly decreased at day 6. Interestingly, compared to day 6, we found increased CD11c + /MHCII med DCs in both the suspension and adherent population at day 8 of SHIP1-KO BM culture, suggesting delayed differentiation at early stages causes the reduction in the total number of BMDCs at day 8 of SHIP1-KO BMDCs. Furthermore, we found that at day 8 there were significantly fewer mature DCs in SHIP1-KO BM cells than in wild-type cells (Table 1) . However, the reduced number of immature DCs (9.99 ± 0.79% in KO vs 15.44 ± 0.80% in WT) at day 6 from SHIP1-KO BM culture implicates that the difference in maturation was due to delayed differentiation of immature DCs from precursors at the early stages ( Figure 2E ). Significant decreases in total and mature BMDCs were also evident in SHIP1-KO BM culture, due to delayed differentiation ( Figure 2F ). Previous studies demonstrated an increase of CD11c + cell population in SHIP1-KO BM culture, 17 but we couldn't find significant increase in total number of CD11c + cells in SHIP1-KO BM culture, compared to wild type BM cultured (Figure 2 C-E). Interestingly, we found many adherent CD11c + /MHCII med immature DCs at the later stages of both wild-type and SHIP1-KO cultures (day 8), but there was rare mature DCs, suggesting that there were BMMs and immature DC attached on BMM-layer (D8 Adh). During maturation by GM-CSF, DCs are released into suspension and are ready for activation, so that major DC population in wild-type suspension cells were mature DCs at day 8 (immature DC 11.2% vs mature DC 25.8 %, Figure 2C ). These data suggest that loss of SHIP1 suppresses optimal DC development through inhibition of cell differentiation at a relatively early stage (before day 6) of development, rather than during maturation process.
Loss of SHIP1 induces cell death during lipopolysaccharide (LPS)-induced DC maturation
It has been well established that LPS treatment could mimic bacteria-induced DC maturation in vitro. For example, LPSinduced maturation increases the expression of MHCII and CD86, and enhances the potential to activate T cell in vitro. 21, 22 As shown in Figure 3 , LPS induced population shifts from immature (CD11c + /CD86 − ) to mature DCs (CD11c + /CD86 + ) in both suspension and adherent cell populations of wild-type BM culture (45.0% and 41.1%, respectively). In contrast, LPS treatment increased the number of DAPI + dead cells and in SHIP1-KO BM culture as assessed by flow cytometry analysis, suggesting a higher sensitivity to LPS-induced cell death than in wild-type BM cells ( Figure 3B ).
Loss of SHIP1 increases the population of BMMs in BM culture
As demonstrated in our earlier morphological study, SHIP1deficient BM culture contained numerous adherent BMMs, but the absence of cellular aggregates of BMDCs ( Figure 1B) . To determine which cells are the major population in SHIP1-KO BM culture, we used an additional cell surface marker, F4/80, which is highly expressed on macrophages. 23 We found that BM cells were mainly composed of two different populations, based on CD11c and F4/80 expression ( Figure 4A ). As expected, both suspension and adherent SHIP1-KO BM cells in culture were mainly composed of CD11c + /F8/40 high BMMs (40.8% and 67.3%, respectively), compared to wild-type BM cells (14.8% and 38.7%, respectively). To confirm BMDCs phenotype, we analyzed MHCII expression of CD11c + /F4/80 low and CD11c + / F4/80 high adherent cells. As shown in Figure 4B , wild type CD11c + /F4/80 low adherent cells (Adh-Q1) were composed of 67.8% MHCII med BMDCs, while CD11c + /F4/80 high adherent cells (Adh-Q2) contained 24.0% BMDCs, indicating that the wild-type adherent BM cells were a mixed population of macrophages and immature DCs. However, SHIP1-KO CD11c + adherent cells had significantly fewer MHCII + BMDCs (29.6% in F4/80 low cells, 34.1% in F4/80 high cells). Thus our data suggest that the loss of SHIP1 promotes macrophage-skewed development and proliferation, leading to defective DC differentiation.
Inhibition of SHIP1 by 3AC in vitro suppresses GM-CSFinduced differentiation into BMDCs
Previous studies have shown that administration of the SHIP1 specific inhibitor 3AC in mice could increase the number of myeloid cells in peripheral blood, tissues and BM without triggering the myeloid-associated lung consolidation, which was commonly observed in SHIP1-KO mice. 7 To examine the in vitro effect of SHIP1 inhibition on the development of BMDCs, 3AC was added to the GM-CSF containing culture medium. We observed that 3AC treatment absolutely blocked GM-CSF-induced colonization of BM cells ( Figure 5A ), which showed striking similarity to the BM cell culture of the SHIP1-KO mice ( Figure 1B) . Of interest, 3AC treated BM culture seems to have increased suspended BMDCs (48.6% in 3AC-treated vs 36.6% in untreated, Figure 5B ), but reduced number of adherent BMDCs (45.0% in 3AC-treated vs 56.3% in untreated). These data may result from a decreased ratio of CD11c − /MHCII low (double negative) suspension cells (13.8% in 3AC-treated vs 51.6% in untreated) rather than an increase in the number of DCs in 3AC treated BM culture. However, like SHIP1-KO BM cells, 3AC treatment skewed the development to F4/80 high cells in both suspension cells (37.7% in 3AC-treated vs 14.9% in untreated) and adherent cells (49.4% in 3AC-treated vs 40.5% in untreated). The cell growth curve as shown in Figure 5C confirmed that 3AC treatment suppresses proliferation of suspension cells, but increases adherent BMMs at later stages of BM culture. In addition, we also found that 3AC did not accelerate cell death during LPS-induced maturation ( Figure 5D ). Taken together, these results indicate that 3AC enhances the development of adherent BMMs in GM-CSF-induced BM culture through inhibition of the growth of suspension cells.
Discussion
Although dendritic cells are rare population of cell found in peripheral tissues, its activation potential to immune response (s) is much higher than any other APCs, including macrophages. Therefore, abnormal differentiation and development of DCs cause imbalance between innate and adaptive immune response, leading to malfunction in the immune system. 24 Host-derived DCs are also critical in priming donor T cells to cause GvHD, and selective targeting of host DCs may be a promising strategy in the pathogenesis of GvHD. 25, 26 SHIP1 deficiency abrogates GvHD through abnormal myeloid-lineage commitment into immune suppressor cells. 27 Consequently, SHIP1-deficient mice are osteoporotic due to increased numbers of hyperresorptive osteroclasts through enhanced osteoclastogenesis of myeloid lineage cells. 28 In contrast, temporal SHIP1 inhibition by 3AC triggers apoptosis of hematopoietic cancer cells, 7 suggesting that SHIP1 contributes to growth and survival of specific cell types, including neoplastic cells. However, the mechanisms underlying the abnormal myeloid development and inducing distinct phenotypes remain to be investigated.
Earlier studies suggested that SHIP1 negatively regulates the GM-CSF-induced generation of DCs from bone marrow precursors. 16, 17 These reports described suppressed maturation of SHIP1-KO BMDCs, in which CD11c + cells were isolated as BMDCs without consideration of morphological differences seen at the early stages of BM culture. Although CD11c + cells obtained in GM-CSF-containing BM culture have been thought pure DC populations over past decades, recent publications clearly demonstrated that CD11c + cells are in fact a heterogeneous group of cells that comprises both BMDCs and BMMs. 19, 29 Two studies used anti-CD86 (B7.2) antibody combined with anti-CD11c antibody to isolate DCs and measure the functional activity of DCs from SHIP1-KO mice compared to wild type DCs and showed that SHIP1-KO DCs isolated from peripheral lymphoid tissues were not functionally impaired with respect to priming of allogeneic T cell responses. 27, 30 However, BMDCs express intermediate or low expression of MHCII and CD86 before antigen-(through Toll-like receptors) induced maturation, and these cells express higher amounts of the same markers during maturation. 20, 29 Because of these heterogeneous phenotypes of BMDCs due to distinct maturation states, analysis using only matured BMDCs might be not sufficient to examine the number and function of BMDCs in in vitro BM culture. 29 In this study, we found that SHIP1 is required for development of BMDCs and identified the prominent function of SHIP1 in differentiation rather than maturation through phenotypic observation and cellular separation between BMDCs and BMMs using flow cytometry. These results clearly defined a role of SHIP1 in the development and immune function of DCs, which has been controversial in previous studies. To investigate the effects of SHIP1 deficiency on differentiation and maturation of BM precursors, we first characterized proliferation and morphological change in BM cells from both SHIP1-KO and wild-type mice. We found increased total cell number ( Figure 2B ), but reduced number of GM-CSFinduced DC colonies in SHIP1-KO culture (Figure 1) . These data suggest that SHIP1 is essential for growth factor-induced DC colonization (ball-shape dense cell colony on macrophage monolayer 2, 24 ). Based on data from flow cytometry analysis, we also defined that growing cells in SHIP1-KO BM culture are mostly macrophage/monocyte like cells, not BMDCs (Figure 4) . In contrast, BM cells from wild-type culture mainly contained F4/80 low (DCs), with some F4/80 high macrophages, suggesting that GM-CSF-induced BMDC differentiation is suppressed in SHIP1-KO BM at an early stage. Because SHIP1-KO mice contain increased number of myeloid cells, 11 BM cells from these mice undergo enhanced proliferation in Table 1 . Composition of BM cell populations on day 8. BM cells from wild-type (WT) and SHIP1-KO (KO) mice were cultured in GM-CSF-containing RPMI 10 media. Cells were harvested and stained with anti-CD11c, anti-MHCII, and anti-CD86 antibodies on day 8. Flow cytometry was performed to determine the proportion of immature and mature DCs in total CD11c + BM cells. The percentages were calculated by number of stained cells per total BM cell number using FlowJo software. Data from three independent experiments were presented as ± SD %.
CD11c+
Total response to GM-CSF, compared to wild-type BM cells. 10 Therefore, increased total and CD11c + cells in SHIP1-deficient BM culture could be due to expansion of myeloid in BM of SHIP1-KO mice, but not enhanced differentiation of BMDC. Further, decreased number of DC colonies could suppress DC development and induce abnormal myeloid development, leading to reducing the number of MHCII + cells (APCs) in peripheral tissue 16, 17 and potential immunosuppressive environment. Antigen presenting cells (APCs) express MHCII molecule on the cell surface, and phagocytosis-triggered signaling pathways can mature these cells for immune response against foreign or internal pathogens through antigen priming. Like every APC, antigen uptake triggers the maturation of DCs, and these changes finally cause DCs to prime/activate immune responses against the foreign materials. As shown in Figure 2 , CD11c + /MHCII med immature BMDCs were clearly separated from CD11c + /MHCII low cells in both suspension and adherent cell populations of wild-type BM culture. However, there were significantly fewer immature BMDCs in SHIP1-KO culture by day 6. At day 8, the percentage of immature DCs has increased compared to day 6 culture, but, due to the reduction of immature DCs, maturation in day 8 SHIP1-KO BM culture was significantly lower than in wild-type BM culture. Therefore, impaired maturation of DCs is likely due to increased ratio of macrophages to immature DCs, rather than perturbation of maturation process itself. Interestingly, we found that treatment of LPS induces cell death of BM cells (40% as DAPI + cells), and changes staining pattern of SHIP1-KO BM cells ( Figure 3B) , while there was no difference in LPS-induced cell death between wild type and 3AC-treated cells. These results suggest that transient SHIP1 inhibition by 3AC enhances development of macrophage without the change in sensitivity to stress during LPS-triggered maturation of BM cells. Although earlier studies showed that LPS treatment increases the SHIP1 level and SHIP1-deficient BMMs and BM mast cells do not display endotoxin tolerance, 31 the role of SHIP1 The specific SHIP1 inhibitor 3AC was designed for blocking enzymatic activity without change in the expression of SHIP1 gene. 7 Because 3AC makes SHIP1 unstable for a certain amount of time, prolonged exposure to 3AC reduces SHIP1 protein levels in a proteasome dependent fashion. 8 Through microscopic observation, we found that there was no GM-CSF-induced colony in 3AC treated BM culture ( Figure 5A ). Although treatment with 3AC increased the percentage of BMMs as observed in SHIP1-KO BM cultures, we were surprised to note a decrease in the number of suspension cells in 3AC treated BM culture, compared to untreated cells ( Figure 5C ). These data suggest that 3AC treatment may provide myeloid favorable niche in BM culture, leading to increased adherent myeloid cells, mainly including macrophages, similar to what was observed in SHIP1-KO mice. Our findings suggest that the use of 3AC has potentially beneficial effects in controlling the population of myeloid cells in inflammation and cancer in agreement with previous studies. 9 Our previous study suggested that ataxia telangiectasia mutated (ATM) plays a role in differentiation of BMDCs through the control of protein expression of Jak2, STAT5, and mTor. 20 Also, we proposed that Akt-mediated signaling pathways are critical for ATM-related regulation for BMDCs development. However, it remains to be investigated which mechanism is involved in SHIP1-mediated regulation during myeloid differentiation from precursors. Thus, time-dependent analysis of GM-CSF-induced signaling pathways could provide essential information to explain how SHIP1 regulates myeloid-lineage commitment in BM. We are currently expanding our study to investigate time-dependent role of SHIP1 in differentiation of BMDCs using SHIP1-KO mice and 3AC treated BM cultures.
In summary, we unveiled the novel role of SHIP1 in myeloid-lineage commitment into DCs and provide critical evidence to modify the misunderstanding function of SHIP1 using the recent framework of defining DCs. As further study, to explain more precise functions of SHIP1 in differentiation and maturation of DCs and macrophages, we need to perform in vitro development study using homologous myeloid precursors, instead of unfractionated BM cells. Also, it would be meaningful study to examine if SHIP1 deficient DCs display distinct immune functions, compared to wild type DCs. Recent works showed that DCs and macrophage have distinct ontogenetic and protein/gene expression signatures during differentiation and maturation. 29, 32 Therefore, ontogenetic and gene expression analysis of the SHIP1-deficient DCs/ macrophages compared to wild type cells will be important further study to reveal the global function of SHIP in management of myeloid lineage.
In conclusion, inhibition of SHIP1 function by a chemical inhibitor or genetic ablation suppresses GM-CSF-induced colonization of BM cells and leads to abnormal differentiation into BMMs. Our findings suggest that SHIP1 plays a direct role in lineage commitment of myeloid precursors rather than in maturation of BMDCs.
Materials and methods
Mice SHIP1 -/+ mice (Stock # 003534) were purchased from Jackson Laboratory (Bar Harbor, ME), and maintained in the pathogen-free animal facility of Rhode Island Hospital/ Brown University. All of mice experiments were approved by the Institution of Animal Care and Use Committee (IACUC). SHIP1-/+ mice were intercrossed to obtain homozygous progeny (SHIP1-KO). Wild type littermates (SHIP1+/+) from same cages with SHIP-KO mice were used as control.
Bone marrow isolation and cell culture to generate BMDCs and BMMs BM cells were isolated from femurs and tibiae of 8~10 weekold male mice. BMDCs were generated as described previously. 33 In brief, BM cells were maintained in RPMI 10 media, supplemented with FBS, penicillin/streptomycin/ amphotericin, and L-glutamine (all from Invitrogen, Carlsbad, CA). Cells were culture for 8-9 day with recombinant murine GM-CSF (10 ng/ml, PeproTech, Rocky Hill, NJ). Suspension cells and adherent cells were harvested by pipetting and scraping, respectively. Photographs were taken at day 3 and day 5 of BM culture under 20 x magnifications using a SPOT microscope camera (SPOT Imaging Solutions, Sterling Heights, MI) attached to TS100F inverted microscope (Nikon). The expression of CD11c and MHCII were used to determine BM differentiation. F4/80 surface protein was used to identify BMMs in CD11c + cells. MHCII and CD86 surface proteins have been examined to determine the level of BMDC maturation. Cultured BM cells were labeled with two or three antibodies, and then analyzed using flow cytometer (LSRII, BD Biosciences) and FlowJo software (FLOWJO), according to manufacturer's instruction.
Chemical reagents and antibodies for flow cytometric analysis
Lipopolysccharide (LPS) was purchased from Sigma-Aldrich (St. Louis, MO), and used for TLR 4-induced maturation of BMDCs (1 μg/ml). 3AC was purchased from Echelon Biosciences (Salt Lake, UT) and dissolved in 100% ethanol. 4ʹ,6-Diamidino-2-Phenylindole (DAPI) was purchased from BioLegend (San Diego, CA). All antibodies were purchased from BioLegend: Alexa Fluor488 anti-MHCII (I-Ab), APC anti-CD11c, PE anti-CD86 (B7-2), PE/Cy7 anti-F4/80, and used at 1:100 dilutions with 1x PBS containing 2% FBS.
Analysis of cell proliferation and cell death of BMDCs
Cells were harvested on indicated day, and diluted with 0.4% trypan blue solution (Invitrogen). Living cells (trypan bluenegative) were counted using hemocytometer (Hausser Scientific, Horsham, PA). DAPI + cells were identified as dead cells during flow cytometry assay.
Statistical analysis
Data unless otherwise indicated are shown as mean values ± standard deviation (SD); p values were calculated with an unpaired two-tailed Student's t-test.
Abbreviations
SHIP1
SH2-containing inositol 5ʹ-phosphatase-1; GM-CSF granulocyte macrophage colony-stimulating factor; MHC II major histocompatibility complex II; BMDC bone marrow-derived dendritic cell; BMM bone marrow-macrophage-like cell; 3AC
3 α-aminocholestane.
